The aim of this study was to determine the association between coding variants in the human tissue kallikrein 1 (KLK1) gene and baseline blood pressure (BP) and antihypertensive response to irbesartan treatment in Chinese hypertensive patients. A total of 1061 hypertensives were recruited and received daily oral dosage of 150 mg irbesartan for 4 weeks. Predose BPs, BPs and blood irbesartan concentrations at postdose on the 28th day were all measured. Common functional singlenucleotide polymorphisms (SNPs) in the KLK1 gene were genotyped. On the basis of the HapMap data of Han Chinese in the Beijing population, two non-synonymous polymorphisms with minor allele frequency40.1, SNP rs5517 (Glu162Lys) and rs5516 (Gln121Glu), were selected. Those with GG genotype in the rs5516 locus had higher average baseline systolic BP (SBP) than CC subjects (b±s.e.: 5.0±2.3, P ¼ 0.033); and no associations of rs5517 with baseline BP (diastolic BP (DBP) and SBP) and BP responses, or rs5516 with baseline DBP and BP response were observed. In a haplotype-based association test for the KLK1 gene, the Haplo-special score analyses identified that haplotype AG was marginally associated with SBP response (specific score: 1.75 for P ¼ 0.08), but not with DBP response. We did not find any associations between haplotypes (GC and AC) and BP responses. The Haplo-GLM analyses showed that, compared with haplotype GC subjects, the subjects with haplotype AG had a marginally greater SBP response (adjusted b ± s.e.: 1.81 ± 0.97, P ¼ 0.06), but DBP response did not differ. This study suggests that rs5516 in the KLK1 gene may be involved in the development of essential hypertension and in the regulation of SBP-lowering response to irbesartan in Chinese hypertensives.
Introduction
Irbesartan, a non-peptide angiotensin II type 1 receptor (AT1R)-specific antagonist, acts at the final step of the renin-angiotensin system by selectively blocking the binding of angiotensin II to AT1R, thereby exhibiting its antihypertensive effect. 1 Although the drug has been proven to have good antihypertensive efficacy with a dose of 150 mg once daily for 6-8 weeks, there are considerable interindividual variations in the therapeutic response to irbesartan, and only 56% of irbesartan-treated patients have a favourable response. [2] [3] [4] [5] Multiple genetic variants as well as environmental risk factors and their interactions may, in part, explain these variations. 6, 7 The kallikrein-kinin system counter-regulates the detrimental actions of the renin-angiotensin system. 8 Beneficial effects of the angiotension-converting enzyme (ACE) inhibition in hypertension and cardiovascular disease are partially attributed to kallikrein increase and kinin accumulation. Many lines of evidence have shown an abnormality of the kallikrein levels in the pathogenesis of hypertension. 8 Epidemiological studies have identified an inverse relationship between blood pressure (BP) and urinary or renal kallikrein levels in patients with essential hypertension. 9 A study using family pedigrees 10 indicated that a dominant gene expressed as renal or urinary kallikrein may be associated with a reduced risk of hypertension. Mice and rats overexpressing human tissue kallikrein gene are permanently hypotensive throughout their lifetime. 11 A single injection of human tissue kallikrein plasmid cDNA constructs into SHRs causes a prolonged reduction of systolic BP (SBP). The extent of BP reduction is dependent on the dose of injected DNA. 12 Human tissue kallikrein 1 (KLK1) protein (EC 3.4.21.35), a key serine protease, is encoded by KLK1 gene located on chromosome 19q13.2-13.4. The KLK1 generates Lys-bradykinin by specific proteolysis of kininogen-1. 13 Gan et al. 14 state that the deduced 262-amino acid KLK1 protein contains a putative signal peptide, followed by a short activating peptide and the protease domain. The active form of the KLK1 is produced by intracellular proteolysis of a short amino-terminal peptide. Measured by RT-PCR, the KLK1 gene highly expresses in 35 human tissues such as kidney, pancreas, salivary gland, thyroid, parotid gland and blood vessels. The human KLK1 gene contains five exons. The sequence of its promoter is highly polymorphic and the variants in the promoter of the kallikrein gene are associated with hypertension. The kallikrein promoter polymorphism regulates gene expression and modifies BP in response to dietary salt intake. 15 Analysis of recombinant kallikrein variants reveals a major decrease in enzyme activity when arginine is replaced by histidine at protein codon 53, and a model of kallikrein derived from crystallographic data suggest that codon 53 is involved in substrate binding. Two common KLK1 gene polymorphisms, single-nucleotide polymorphism (SNP) rs5515 (Arg53His) and rs5516 (Gln121Glu)) have long been implicated in the pathogenesis of human essential hypertension. [16] [17] [18] SNP rs5517 (Glu162Lys) in exon 4 of the KLK1 gene has attracted a lot of attention recently. A large-scale case-control study in a Chinese Han population with tag SNPs approach suggested that SNP rs5517 in the KLK1 gene was significantly associated with essential hypertension. 19 The KLK1 has a critical role in the cardioprotective effect of ACE inhibitors in acute myocardial ischaemia. 20 Genetically engineered mice deficient in the KLK1 and kinin confirm the role of the KLK1 in the cardioprotection elicited by AT1R blockade. 21 These data suggest that the KLK1 may be involved in the progression of cardiovascular diseases, and further alter ACE inhibition therapeutic response. To investigate whether the KLK1 has a critical role in the development of essential hypertension and in the drug response to Irbesartan, we recruited 1061 essential hypertensive patients with administration of daily oral dosage of 150 mg irbesartan for 28 consecutive days. The blood samples of patients were collected to determine the genotypes of the protein coding SNP rs5516 and rs5517 in KLK1 gene. The relationship between these two KLK1 functional genetic variants and the baseline BP level as well as BP-lowering response to irbesartan treatment were investigated.
Materials and methods

Study population
Patients with mild-to-moderate hypertension were enrolled from two adjacent counties, Taihu and Dongzhi, in Anhui Province, China, from April 2003 to January 2004. In brief, hypertensive subjects who met the following criteria were enrolled: (1) SBP, 140-200 mm Hg or diastolic BP (DBP), 90-115 mm Hg; (2) aged 35-65 years old; and (3) not taking any antihypertensive medications within 4 weeks before the study. Subjects with a history of any of the following conditions were excluded: secondary hypertension, pregnancy, hypercalcaemia, chronic cardiovascular disease, chronic cerebrovascular disease, chronic liver or renal diseases, or body mass index 433 kg m À2 . The study was approved by the Ethics Committee of Anhui Medical University, Hefei, China. The purpose and procedures of the study were carefully explained to all participants, and a written informed consent was obtained.
Measurement of BPs and biometric variables
BPs were measured by well-trained nurses using a mercury-gravity manometer with appropriate sized cuffs after the subjects kept silent in a seated pose for half an hour without drinking tea or smoking. Triplicate measurements were carried out on the left arm with a 30-s interval between each reading. We defined SBP as Korotkoff phase I (appearance of sound) and DBP as Korotkoff phase V (disappearance of sound). The mean of the three BP measurements was used in statistical analysis. If the difference between measurements was 44 mm Hg, the patient was asked to rest for 5 min, and then the measurements were repeated. The subjects' age, gender, weight, height, smoking and drinking status and other demographic factors were also measured.
Irbesartan treatment and blood sample collection All subjects were instructed to take a 150-mg tablet of irbesartan (manufactured by Sanofi-Synthelabo, Hongzhou, China), once daily, fasting in the morning, for 28 consecutive days. The 1st and the 28th doses of the subjects were administered in our study centre. Subjects were excluded from our study if they were unable to tolerate the drug therapy or took any other medications during the follow-up. Blood samples were collected in vacutainers containing heparin as an anticoagulant at the predose time point of the first day and at the 24-h time point after the 27th day of drug administration. Plasma was obtained from blood samples after centrifuging (5417R Centrifuge, Eppendorf AG, Hamburg, Germany) at 4 1C and stored at À80 1C before analysis.
Determination of plasma irbesartan by high performance liquid chromatography fluorescence Plasma irbesartan concentrations were measured by high performance liquid chromatography fluorescence. Standard curves of irbesartan were constructed using a series of standard working solutions dissolved with methanol. The lower limit of detection was 5 ng ml À1 , and the upper limit of quantification was 5000 ng ml À1 . Mean accuracy ranged from 97 to 104%. Within-and between-run precision (% RSD) were o8% at all concentration levels. Quantitation of irbesartan was measured by comparing high performance liquid chromatography peak areas with those of authentic standards, with reference to an internal standard.
DNA extraction and genotyping
Venous blood samples were collected from all participants. Genomic DNA was extracted using the QIAamp Blood Kit (Qiagen, Valencia, CA, USA) by standard techniques and stored at À20 1C until genotypic analysis was performed. SNP rs5516 and rs5517 in KLK1 gene were genotyped using the Taqman allelic discrimination method (Applied Biosystems, Foster City, CA, USA). 22 
Statistical analysis
The SAS statistical program (Release 8.0, SAS Institute, Cary, NC, USA) was used for data analysis. Descriptive statistical analyses were presented as percentages for categorical variables and mean values with s.d. for continuous variables. BP response was defined as BP before treatment minus BP on the 28th day. Multiple linear regression analyses were used to assess the influences of specific SNPs on the baseline BP and BP response, with adjustment of potential confounders, including age, sex, body mass index, smoking status, alcohol consumption, plasma concentration of irbesartan, educational level, occupation and county.
Haplotypes of SNPs rs5517 and rs5516 were estimated by expectation-maximization algorithm. Association between haplotypes and phenotypes (baseline BP and BP response) were examined by score test and generalized linear model test. 23 Both Haplo.score and Haplo.glm were implemented in the Haplo.stats software developed using the R language.
Results
Demographic and clinical characteristics of the study population Totally, 1061 subjects from two adjacent rural communities in Anhui Province, China, with complete genotype and phenotype information were analysed. The genotype distribution of SNP rs5516 and rs5517 were not deviated from Hardy-Weinberg equilibriums (
respectively. The subjects' mean age, body mass index, baseline SBP and DBP, SBP and DBP reductions and trough irbesartan concentration are shown in Table 1 . Among hypertensive subjects, 43.7% are male; 35.5% were current smokers; 24.4% were current alcohol drinkers; and 84.6% were farmers.
Single-locus association test
We used multiple linear regression models to estimate the association of SNP rs5517 and rs5516 with baseline BPs (Table 2 ) and BP responses ( Haplotype-based association test for KLK1 gene Previous study result 19 supported that the optimal rs5516 and rs5517 set was selected as tSNPs that efficiently covered both common haplotype and ungenotyped variants of the KLK1 gene. Tables 4  and 5 displayed the results of haplotype-specific (Haplo-score) and haplotype-global (Haplo-GLM) analyses for the association between the SNP rs5517-rs5516 haplotypes and baseline BPs and BP responses. Only three haplotypes with a frequency 40.01 (G-C, A-C and A-G) were observed. Haplotype-based association tests were performed with adjustment for baseline BPs, age, sex, body mass index, smoking status, alcohol consumption, plasma concentration of irbesartan, education and occupation with the global score test. In Table 4 , no significant associations were detected for SNP rs5517-rs5516 haplotype with baseline DBP (global score ¼ 1.36, df ¼ 2, P ¼ 0.51) and SBP (global score ¼ 2.30, df ¼ 2, P ¼ 0.32). In the Haplo-special score analyses, we did not observe any haplotype (G-C, A-C and A-G) that was significantly associated with baseline DBP (specific score: À0.43, À0.61 and 1.13 for P ¼ 0.67, Effects of protein-coding polymorphisms in the KLK1 gene S Jiang et al 0.55 and 0.26, respectively) or with baseline SBP (specific score ¼ 0.74, À1.50 and 0.63 for P ¼ 0.46, 0.13 and 0.53, respectively). The Haplo-GLM analyses showed that, compared with haplotype GC subjects, the subjects with haplotype AC and AG did not have significantly greater baseline SBP and DBP. As shown in Table 5 , no marginally significant associations were detected for KLK1 haplotypes with DBP response (global score ¼ 0.95, df ¼ 2, P ¼ 0.62) or SBP response (global score ¼ 3.49, df ¼ 2, P ¼ 0.17). In the Haplospecial score analyses, we found that haplotype AG was marginally associated with SBP response (specific score: 1.75 for P ¼ 0.08) but not with DBP response. Moreover, haplotypes (GC and AC) were not associated with SBP response or DBP response. The Haplo-GLM analyses showed that, compared with haplotype GC subjects, the subjects with haplotype AG had a marginally greater SBP response (adjusted b ± s.e.: 1.81 ± 0.97, P ¼ 0.06), but not DBP response. The haplotype AC did not show significant associations with BP responses.
Discussion
Our results suggest that the rs5516 polymorphism in exon 3 of the KLK1 gene, and their reconstructed haplotype AG, are associated with baseline SBP and SBP reduction to antihypertensive treatment with irbesartan. Consistent with earlier finding in Japanese, 24 SNP rs5517 did not associate with either baseline BPs or BP responses to irbesartan treatment in Chinese hypertensives.
KLK1 belongs to a subgroup of serine proteinases and processes low molecular weight kininogen substrates to release vasoactive kinin peptides. Intact kinins bind to bradykinin B2 receptors, whereas kinin metabolites produced by enzymes such as kiniases I and II and neutral endopeptidase, bind to bradykinin B1 receptors. The binding of kinins to their respective receptors activates signalling pathways such as NO-cGMP and prostacyclin-cAMP, which trigger a broad spectrum of biological effects including endothelial function in arteries, vasodilation, smooth Both Haplo-score and Haplo-GLM analyses were adjusted for baseline DBP, baseline SBP, age, BMI, smoking and alcohol status, education levels, occupation, community and plasma concentration of irbesartan. b BP response was defined as BP before treatment minus BP on the 28th day.
Effects of protein-coding polymorphisms in the KLK1 gene S Jiang et al muscle contraction and relaxation, inflammation and pain. Previously reported evidences indicate that the cardioprotective effects of ACE inhibitors in ischaemia-reperfusion injury are the result of the protection of endogenous kinins from degradation rather than inhibition of Ang II formation. 20, 25 Genetically engineered mice deficient in KLK1 ascertained the role of KLK1 in the cardioprotection elicited by AT1R blockade in ischemia-reperfusion injury. 21 Therefore, it is likely that KLK1 may directly contribute to AT1R inhibition of irbesartan therapeutic efficacy. Our findings have found that the KLK1 rs5516 polymorphism and reconstructed haplotype AG marginally alter SBP response to irbesartan treatment.
The KLK1 rs5517 polymorphism is a G to A transition, which replaces Glu (GAA) to Lys (AAA) at position 162. A large-scale case-control study 19 identified that in a Chinese Han population although the rs5517 polymorphism in the KLK1 gene was significantly associated with essential hypertension, the two different studies consistently found that the rs5516 was significantly associated with hypertension risk (P ¼ 0.0298) 19 or higher baseline SBP level in our hypertensive patients (P ¼ 0.033). Our present study reports that the frequencies of rs5517 GG, GA and AA in the hypertensive group were 34.21, 49.11 and 16.68%, respectively, whereas the frequencies of CC, CG and GG for rs5516 were 62.68, 32.99 and 4.33%, respectively; which were similar in distribution to the hypertensive subgroups in the previous study. 19 Hong et al. 26 showed that the KLKI Glu162Lys polymorphism functionally affects plasma creatinine levels, and suggested that the genetic variant is a risk factor for a decline in renal plasma creatinine clearance rate in hypertensive individuals. However, we did not find the rs5517 polymorphism is associated with higher baseline BP levels. The different conclusions are largely explained by the two different study designs (a case-control study vs a prospective cohort study).
The SNP rs5516 is a C to G transition located in exon 3, which causes Gln to Glu substitution at position 121. Our results show that SNP rs5516 (Gln121Glu), but not SNP rs5517 (Glu162Lys), is significantly associated with baseline SBP in Chinese hypertensives, which is different from the results found in Caucasian populations. 18, 27 To date, molecular evidence indicated that the locus at position 162 (rs5517) of the KLK1 gene is not in the catalytic triads (His41, Asp96 and Ser189) or any known essential binding pockets (S1, S2, S1
0 , S2 0 and kallikrein loop) of the protein, 28 and in vitro synthesis of recombinant kallikrein variants of SNP rs5516 (Q121E) shows it does not reduce enzyme activity. 27 The result of an in vivo study does not support the hypothesis that the Q121E SNP in the KLK gene affects either endothelium-dependent vasodilatation or endothelium-independent vasodilatation in humans. 29 However, we speculate that rs5516 is most likely a functional common polymorphism and subjects with rs5516 GG genotype of the KLK1 gene may have decreased enzyme activity or in linkage disequilibrium with functional variants and subsequent increased BP level.
Recently, Slim et al. 27 reported that there is an SNP Arg53-His in exon 3 of KLK1, and found association with significant decrease in urinary kallikrein activity. When arg53 is replaced by histidine, analysis of recombinant kallikrein variants revealed a major decrease in enzyme activity. A model of kallikrein derived from crystallographic data suggest that arg53 is involved in substrate binding, and individuals with R53H have on average a 50-60% reduction in urinary kallikrein activity. 30 The HapMap project data available in Chinese population exhibit that there are no any frequencies of both rs5516 and rs5515 loci, which indicated it is likely that rs5516 is in strong linkage disequilibrium with known rs5515 (Arg53His) functional variant. YRI population data further support the rs5515 and rs5516 are in complete LD (D 0 ¼ 1). A limitation of this study was that the SNPs in the promoter region were not included. In fact, several studies have provided evidence of an association of regulatory polymorphisms of the KLK1 gene with hypertension and related disease. [13] [14] [15] In conclusion, this study suggests that rs5516 in the KLK1 gene may be involved in the development of essential hypertension and in the regulation of SBP-lowering response to irbesartan in Chinese hypertensives. Functional investigations are needed to elucidate their relationships.
acknowledge the assistance and cooperation of the faculty and staff of the Anhui Medical University and thank all of the participants in our study, as well as Dr Zhong Guisheng (Cornell University) who helped edit this manuscript. This study was conducted in accordance with the current regulations of the People's Republic of China.
